This population-based cross-sectional study evaluates the clinical value of electroretinography and visual evoked potentials in childhood brain tumor survivors. A flash electroretinography and a checkerboard reversal pattern visual evoked potential (or alternatively a flash visual evoked potential) were done for 51 survivors (age 3.8-28.7 years) after a mean follow-up time of 7.6 (1.5-15.1) years. Abnormal electroretinography was obtained in 1 case, bilaterally delayed abnormal visual evoked potentials in 22/51 (43%) cases. Nine of 25 patients with infratentorial tumor location, and altogether 12 out of 31 (39%) patients who did not have tumors involving the visual pathways, had abnormal visual evoked potentials. Abnormal electroretinographies are rarely observed, but abnormal visual evoked potentials are common even without evident anatomic lesions in the visual pathway. Bilateral changes suggest a general and possibly multifactorial toxic/adverse effect on the visual pathway. Electroretinography and visual evoked potential may have clinical and scientific value while evaluating long-term effects of childhood brain tumors and tumor treatment.
Steliarova-FoucherEStillerCKaatschP. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet. 2004;364(9451):2097–2105.
2.
GattaGCapocacciaRStillerC. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol. 2005;23(16):3742–3751.
3.
DickermanJD. The late effects of childhood cancer therapy. Pediatrics. 2007;119(5):554–568.
HarbertMJYeh-NayreLAO’HalloranHSLevyMLCrawfordJR. Unrecognized visual field deficits in children with primary central nervous system brain tumors. J Neurooncol. 2012;107(3):545–549.
6.
ChouSYDigreKB. Neuro-ophthalmic complications of raised intracranial pressure, hydrocephalus, and shunt malfunction. Neurosurg Clin N Am. 1999;10(4):587–608.
7.
NguyenTNPolomenoRCFarmerJPMontesJL. Ophthalmic complications of slit-ventricle syndrome in children. Ophthalmology. 2002;109(3):520–525.
8.
MihalceaOArnoldAC. Side effect of head and neck radiotherapy: optic neuropathy. Oftalmologia. 2008;52(1):36–40.
9.
BehbehaniR. Clinical approach to optic neuropathies. Clin Ophthalmol. 2007;1(3):233–246.
10.
LessellS. Friendly fire: neurogenic visual loss from radiation therapy. J Neuroophthalmol. 2004;24(3):243–250.
11.
GuptaADhawahir-ScalaFSmithAYoungLCharlesS. Radiation retinopathy: case report and review. BMC Ophthalmol. 2007;7:6.
12.
SeregardSPelayesDESinghAD. Radiation therapy: posterior segment complications. Dev Ophthalmol. 2013;52:114–123.
13.
YouYGuptaVKLiJCKlistornerAGrahamSL. Optic neuropathies: characteristic features and mechanisms of retinal ganglion cell loss. Rev Neurosci. 2013;24(3):301–321.
14.
PerlmanI. The electroretinogram: ERG. In: KolbHFernandezENelsonR, eds. Webvision: The Organization of the Retina and Visual System. Salt Lake City: University of Utah Health Sciences Center; 2007. Available at: http://webvision.med.utah.edu/book/electrophysiology/the-electroretinogram-erg/. Accessed August 15, 2014.
15.
CreelDJ. Visually evoked potentials. In: KolbHFernandezENelsonR, eds. Webvision: The Organization of the Retina and Visual System. Salt Lake City: University of Utah Health Sciences Center; 2012. Available at: http://webvision.med.utah.edu/book/electrophysiology/the-electroretinogram-erg/. Accessed August 15, 2014.
16.
FalsiniBZiccardiLLazzareschiI. Longitudinal assessment of childhood optic gliomas: relationship between flicker visual evoked potentials and magnetic resonance imaging findings. J Neurooncol. 2008;88(1):87–96.
17.
KellyJPWeissAH. Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1. Neuro Oncol. 2013;15(11):1560–1567.
18.
IlveskoskiISaarinenUMPerkkiöM. Chemotherapy with the “8 in 1” protocol for malignant brain tumors in children: a population-based study in Finland. Pediatr Hematol Oncol. 1996;13(1):69–80.
19.
ZeltzerPMBoyettJMFinlayJL. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832–845.
20.
MarmorMF. An updated standard for clinical electroretinography. Arch Ophthalmol. 1995;113(11):1375–1376.
21.
ShurinSBRekateHLAnnableW. Optic atrophy induced by vincristine. Pediatrics. 1982;70(2):288–291.
22.
O’BrienMETongeKBlakePMoskovicEWiltshawE. Blindness associated with high-dose carboplatin. Lancet. 1992;339(8792):558.
23.
CaraceniAMartiniCSpattiGThomasAOnofrjM. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand. 1997;96(4):260–261.
24.
WangMYArnoldACVintersHVGlasgowBJ. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol. 2000;130(3):367–368.
25.
Weisfeld-AdamsJDDuttonGNMurphyDM. Vincristine sulfate as a possible cause of optic neuropathy. Pediatr Blood Cancer. 2007;48(2):238–240.
HilliardLMBerkowRLWattersonJBallardEABalzerGKMoertelCL. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol. 1997;28(4):310–313.
28.
KraussGLJohnsonMAMillerNR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998;50(3):614–618.
YorkDHPulliamMWRosenfeldJGWattsC. Relationship between visual evoked potentials and intracranial pressure. J Neurosurg. 1981;55(6):909–916.
31.
LaronMChengHZhangBSchiffmanJSTangRAFrishmanLJ. Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients. Mult Scler. 2010;16(4):412–426.
32.
ZhaoZLanYBaiS. Late-onset radiation-induced optic neuropathy after radiotherapy for nasopharyngeal carcinoma. J Clin Neurosci. 2013;20(5):702–706.
33.
Rodriguez-MenaDAlmarceguiCDolzI. Electropysiologic evaluation of the visual pathway in patients with multiple sclerosis. J Clin Neurophysiol. 2013;30(4):376–381.
